Ultrastructural changes in parasites induced by nanoparticle-bound pentamidine in a Leishmania major/mouse model.
Drug targeting enhances drug efficacy. This principle was tested in the treatment of an experimental visceral leishmaniasis. Using transmission electron microscopy (TEM) we localized pentamidine-loaded polymethocrylate nanoparticles in the liver of mice infected with Leishmania major and compared the ultrastructural changes in the parasites of these mice when they were treated with bound versus free pentamidine. Between days 13 and 17 after infection, loaded nanoparticles treated group were injected i.v. with 3 doses of 0.17 mg/kg bound pentamidine loaded on 2 x 10(11) nanospheres; control groups received 2 x 10(11) unloaded nanospheres. Drug reference control groups received five doses of 200 mg/kg pentavalent antimony (Glucantime) or three doses of free pentamidine (0.17 mg/kg or 2.28 mg/kg). Mice treated with bound pentamidine displayed a 77% reduction in their parasite burden versus the untreated controls. Nanoparticles were located by TEM inside parasitized Küpffer cells, in the phagolysosomes without entering the Leishmania. The low dose of 0.17 mg/kg bound pentamidine damaged the Leishmania to the same extent as 2.28 mg/kg of free pentamidine (the usual dose in human chemotherapy). In the parasites inside the Küpffer cells, TEM showed a swollen mitochondrian with loss of cristae, destruction or fragmentation of the kinetoplast, loss of ribosomes and destruction of parasite structures except for the subpellicular microtubules. This study therefore shows that a dose of bound pentamidine 13 times smaller than the usual dose of free pentamidine has a similar effect on the parasite.
Fusai
T
T
Médecin des Armées, IMTSSA, Marseille.
Boulard
Y
Y
Durand
R
R
Paul
M
M
Bories
C
C
Rivollet
D
D
Astier
A
A
Houin
R
R
Deniau
M
M
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D004195:Disease Models, Animal; D004337:Drug Carriers; D007728:Kupffer Cells / Q000469:parasitology / Q000648:ultrastructure; D018320:Leishmania major / Q000648:ultrastructure*; D007898:Leishmaniasis, Visceral / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008807:Mice, Inbred BALB C; D008854:Microscopy, Electron; D010419:Pentamidine / Q000008:administration & dosage / Q000494:pharmacology*; D011109:Polymethacrylic Acids
D000981:Antiprotozoal Agents; D004337:Drug Carriers; D011109:Polymethacrylic Acids; D010419:Pentamidine